Current News
ViroPharma Incorporated (NASDAQ: VPHM) today announced that it completed its acquisition of DuoCort Pharma AB. The acquisition further expands ViroPharma’s orphan disease commercial product pipeline. ViroPharma has paid an upfront closing cost of 220 million Swedish kroner (SEK) or $33.6 million in US dollars (USD). Additionally, there are contingent milestone payments of up to 860 million SEK.
DuoCort Pharma’s Orphan Drug Plenadren® Granted European Marketing Authorization for Adrenal Insufficiency
Press Release Nov 07, 2011 07:00 EST
The Swedish specialty pharma company, DuoCort Pharma, announced today that the European Commission has granted a European Marketing Authorisation for Plenadren® (hydrocortisone, modified release tablet), an orphan drug for treatment of adrenal insufficiency in adults, bringing these patients their first pharmaceutical innovation in over 50 years.
DuoCort AB announces it has signed a definitive agreement to sell DuoCort Pharma AB and its orphan drug Plenadren® to the biopharmaceutical company ViroPharma Incorporated. Plenadren® is a new treatment for adrenal insufficiency, also called Addison´s disease. The total potential deal value exceeds one billion SEK of which 220 million SEK will be paid by ViroPharma on closing.
Pictures
Videos
-
DuoCort-A story about a pill
DuoCort has developed an improved treatment for patients with adrenal insufficiency, a rare disease for which DuoCort has orphan drug designations in Europe and the USA. The new treatment is a dual release. This means it has an outer layer that immediately releases the drug and an inner core that releases the drug over the day to mimic the body´s own release of cortisol.
